Evidence map›Paper›PMID 31639007›Full record

SynthesisBMC medicine2019

Age-treatment subgroup analyses in Cochrane intervention reviews: a meta-epidemiological study.

Patrick Liu, John P A Ioannidis, Joseph S Ross, Sanket S Dhruva, Anita T Luxkaranayagam, Vasilis Vasiliou, Joshua D Wallach

Open access · goldAbstract readMeta-Analysis
In one paragraph

Synthesis in BMC medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Observational
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Patrick LiuYale School of Medicine, New Haven, CT, 06510, USA.
John P A IoannidisMeta-Research Innovation Center at Stanford (METRICS), Stanford School of Medicine, Stanford, CA, 94305, USA.
Joseph S RossCenter for Outcomes Research and Evaluation (CORE), Yale-New Haven Health System, New Haven, CT, 06510, USA.
Sanket S DhruvaDepartment of Medicine, University of California, San Francisco School of Medicine, San Francisco, USA.
Anita T LuxkaranayagamUniversity of Connecticut, Storrs, CT, 06269, USA.
Vasilis VasiliouDepartment of Environmental Health Sciences, Yale School of Public Health, New Haven, CT, 06510, USA.
Joshua D WallachCenter for Outcomes Research and Evaluation (CORE), Yale-New Haven Health System, New Haven, CT, 06510, USA. Joshua.wallach@yale.edu.ORCID 0000-0002-2816-6905
Yale University · USProtein Metrics (United States) · USUniversity of California, San Francisco · USUniversity of Connecticut · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

backgroundThere is growing interest in evaluating differences in healthcare interventions across routinely collected demographic characteristics. However, individual subgroup analyses in randomized controlled trials are often not prespecified, adjusted for multiple testing, or conducted using the appropriate statistical test for interaction, and therefore frequently lack credibility. Meta-analyses can be used to examine the validity of potential subgroup differences by collating evidence across trials. Here, we characterize the conduct and clinical translation of age-treatment subgroup analyses in Cochrane reviews.

methodsFor a random sample of 928 Cochrane intervention reviews of randomized trials, we determined how often subgroup analyses of age are reported, how often these analyses have a P < 0.05 from formal interaction testing, how frequently subgroup differences first observed in an individual trial are later corroborated by other trials in the same meta-analysis, and how often statistically significant results are included in commonly used clinical management resources (BMJ Best Practice, UpToDate, Cochrane Clinical Answers, Google Scholar, and Google search).

resultsAmong 928 Cochrane intervention reviews, 189 (20.4%) included plans to conduct age-treatment subgroup analyses. The vast majority (162 of 189, 85.7%) of the planned analyses were not conducted, commonly because of insufficient trial data. There were 22 reviews that conducted their planned age-treatment subgroup analyses, and another 3 reviews appeared to perform unplanned age-treatment subgroup analyses. These 25 (25 of 928, 2.7%) reviews conducted a total of 97 age-treatment subgroup analyses, of which 65 analyses (in 20 reviews) had non-overlapping subgroup levels. Among the 65 age-treatment subgroup analyses, 14 (21.5%) did not report any formal interaction testing. Seven (10.8%) reported P < 0.05 from formal age-treatment interaction testing; however, none of these seven analyses were in reviews that discussed the potential biological rationale or clinical significance of the subgroup findings or had results that were included in common clinical practice resources.

conclusionAge-treatment subgroup analyses in Cochrane intervention reviews were frequently planned but rarely conducted, and implications of detected interactions were not discussed in the reviews or mentioned in common clinical resources. When subgroup analyses are performed, authors should report the findings, compare the results to previous studies, and outline any potential impact on clinical care.

Indexed as

Data Interpretation, StatisticalResearch DesignReview Literature as TopicAge DistributionAge FactorsEpidemiologic Research DesignEpidemiologic StudiesFemaleHumansPrecision MedicineRandomized Controlled Trials as TopicAge subgroupsHeterogeneity of treatment effectsPrecision medicineSubgroup analyses

Identifiers

PMID31639007
PMCPMC6805640
OpenAlexW2981175622

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.